Latest Conference Articles | OncLive

Latest Conference Articles

Dr. Hamilton on the Results of the nextMONARCH Trial in Patients With HR+/HER2- Breast Cancer

Dr. Hamilton on the Results of the nextMONARCH Trial in Patients With HR+/HER2- Breast Cancer

September 23rd 2020, 11:46pm

ESMO Congress

Erika P. Hamilton, MD, discusses ​the final overall survival results from the ​randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive​, HER2-negative metastatic breast cancer.

VERU-111 Demonstrates Preliminary Viability in Pretreated mCRPC

VERU-111 Demonstrates Preliminary Viability in Pretreated mCRPC

September 23rd 2020, 5:30pm

Continuous administration of the novel tubulin inhibitor VERU-111 proved to be safe and demonstrated antitumor activity, evidenced by prostate-specific antigen reductions, objective tumor responses, and durable activity, in men with previously treated metastatic castration-resistant prostate cancer.

Dr. Kelly on the Rationale for the CheckMate-577 Trial in Esophageal/GEJ Cancer

Dr. Kelly on the Rationale for the CheckMate-577 Trial in Esophageal/GEJ Cancer

September 21st 2020, 11:47pm

ESMO Congress

Ronan J. Kelly, MD, MBA, discusses the rationale to conduct the phase 3 CheckMate-577 study in esophageal or gastroesophageal junction cancer.

Atezolizumab Plus Bevacizumab/Chemo Fails to Significantly Improve PFS in Ovarian Cancer

Atezolizumab Plus Bevacizumab/Chemo Fails to Significantly Improve PFS in Ovarian Cancer

September 21st 2020, 11:45pm

ESMO Congress

The addition of atezolizumab to a backbone comprised of bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.

Dr. Bardia on the Results of the ASCENT Trial in Previously Treated Metastatic TNBC

Dr. Bardia on the Results of the ASCENT Trial in Previously Treated Metastatic TNBC

September 21st 2020, 11:43pm

ESMO Congress

Aditya Bardia, MD, MPH, discusses the results of the randomized phase 3 ASCENT trial in previously treated, metastatic triple-negative breast cancer.

Dr. Coleman on the Clinical Implications of the innovaTV 204 Trial in Cervical Cancer

Dr. Coleman on the Clinical Implications of the innovaTV 204 Trial in Cervical Cancer

September 21st 2020, 11:40pm

ESMO Congress

Robert L. Coleman, MD, FACOG, FACS, discusses the clinical implications of the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 trial in women with previously treated recurrent or metastatic cervical cancer.

Study Demonstrates Improved Responses With Molecularly-Guided Therapy in mRCC

Study Demonstrates Improved Responses With Molecularly-Guided Therapy in mRCC

September 21st 2020, 10:33pm

ESMO Congress

Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial demonstrated clinical evidence to support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma.

Cemiplimab Demonstrates Frontline Potential in Advanced PD-L1+ NSCLC

Cemiplimab Demonstrates Frontline Potential in Advanced PD-L1+ NSCLC

September 21st 2020, 10:23pm

ESMO Congress

Cemiplimab-rwlc monotherapy led to a significant improvement in overall survival and progression-free survival versus platinum-doublet chemotherapy as first-line therapy in patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cell.

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21st 2020, 9:40pm

ESMO Congress

The feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demonstrated in the phase 1b TRAMUNE trial.

Tisotumab Vedotin Elicits Encouraging Responses in Recurrent/Metastatic Cervical Cancer

Tisotumab Vedotin Elicits Encouraging Responses in Recurrent/Metastatic Cervical Cancer

September 21st 2020, 9:00pm

ESMO Congress

Tisotumab vedotin demonstrated an objective response rate of 24% in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab, if eligible.

x